Holen Sie sich die Stockscreener-App
18.17
4.92%
-0.94
Schlusskurs vom Vortag:
$19.11
Offen:
$19.28
24-Stunden-Volumen:
602.62K
Relative Volume:
1.26
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-12.52%
1M Leistung:
-27.84%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.83
$19.60
1-Wochen-Bereich:
$17.83
$20.83
52-Wochen-Spanne:
$14.14
$26.91
Omada Health Inc Stock (OMDA) Company Profile
Firmenname
Omada Health Inc
Sektor
Branche
Telefon
888-987-8337
Adresse
611 GATEWAY BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie OMDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMDA
Omada Health Inc
|
18.17 | 1.11B | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
270.50 | 44.75B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
65.69 | 12.29B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
100.73 | 8.92B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
46.42 | 9.04B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
34.79 | 6.66B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omada Health Inc Stock (OMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-09-05 | Eingeleitet | Robert W. Baird | Neutral |
| 2025-07-01 | Eingeleitet | Barclays | Overweight |
| 2025-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-01 | Eingeleitet | Evercore ISI | Outperform |
| 2025-07-01 | Eingeleitet | Goldman | Buy |
| 2025-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Needham | Buy |
Alle ansehen
Omada Health Inc Aktie (OMDA) Neueste Nachrichten
Omada Health to Participate in Evercore Healthcare Conference - The Manila Times
United States 7MM Digital Therapeutics for Diabetes Market: FDA - openPR.com
Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach - TipRanks
OMDA: BMO Capital Initiates Coverage with "Outperform" Rating | - GuruFocus
Thought bubble: Omada's about-face - Axios
Omada Health initiated with an Outperform at BMO Capital - TipRanks
Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities - TipRanks
EBIT per share of Omada Health, Inc. – MUN:U76 - TradingView
Inside Omada's pivot toward GLP-1 prescriptions - Axios
Cash from financing activities of Omada Health, Inc. – FWB:U76 - TradingView
Omada Health Reports Strong Q3 2025 Growth - MSN
How Trump’s GLP-1 move may affect telehealth companies’ fortunes - Modern Healthcare News
Free cash flow per share of Omada Health, Inc. – MUN:U76 - TradingView
Omada Health, Inc. Earnings and Revenue – MUN:U76 - TradingView
Omada Health (OMDA): Assessing Valuation After Recent Stock Declines - Yahoo Finance
Latin America Digital Therapeutics Market Poised - openPR.com
Omada Health Stock Jumps Into Retail Focus As Wall Street Lifts Price Targets After ‘Beat And Raise’ Quarter, GLP-1 Push - Stocktwits
Omada Health, Inc. Balance Sheet – FWB:U76 - TradingView
Omada Health raises FY25 revenue view to $251.5M-$254.5M from $235M-$241M - MSN
Omada Health reports Q3 EPS (6c), consensus (7c) - MSN
Omada Health Reports Strong Growth and Innovation - MSN
Omada Health price target raised to $32 from $30 at Morgan Stanley - MSN
Omada Health price target raised to $28 from $27 at Evercore ISI - MSN
Evercore ISI Group Maintains Omada Health (OMDA) Outperform Recommendation - MSN
Why Omada Health is finally prescribing Ozempic as TrumpRx slashes GLP-1 weight-loss drug costs - Business Insider
Omada Health Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Omada Health to prescribe GLP-1s - TechTarget
Evercore ISI Group Raises Price Target for OMDA to $28.00 | OMDA Stock News - GuruFocus
Omada Health, Inc.: Strong Revenue Momentum and Strategic Partnerships Drive Buy Rating - TipRanks
Omada Health to present RWE on behavior change program at ObesityWeek - MSN
Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy Rating - TipRanks
Omada Health Inc (OMDA) Q3 2025 Earnings Call Highlights: Record Membership Growth and ... By GuruFocus - Investing.com Canada
Omada Health Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Omada Health Q3 2025 sees revenue growth, stock dips - Investing.com India
Omada Health announces GLP-1 prescribing capability - TipRanks
Compared to Estimates, Omada Health, Inc. (OMDA) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Omada Health announces GLP-1 prescribing capability to support growing member population - MarketScreener
Earnings Flash (OMDA) Omada Health, Inc. Reports Q3 Revenue $68.0M, vs. FactSet Est of $61.3M - MarketScreener
Omada Health, Inc. (OMDA) Q3 FY2025 earnings call transcript - Yahoo Finance
Omada Health Reports Third Quarter 2025 Results - The Manila Times
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population - The Manila Times
Omada Health (NASDAQ: OMDA) to offer GLP-1 prescribing nationwide; members up 53% YoY - Stock Titan
[8-K] Omada Health, Inc. Reports Material Event | OMDA SEC FilingForm 8-K - Stock Titan
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows - CNBC
Earnings To Watch: Omada Health Inc (OMDA) Reports Q3 2025 Resul - GuruFocus
Earnings To Watch: Omada Health Inc (OMDA) Reports Q3 2025 Result - Yahoo Finance
Revenue per share of Omada Health, Inc. – NASDAQ:OMDA - TradingView
EBITDA per share of Omada Health, Inc. – SWB:U76 - TradingView
ETFs Investing in Omada Health, Inc. Stocks - TradingView
Omada Health (Nasdaq: OMDA) shows 0.8% after GLP-1 discontinuation, 63.2% maintained/lost - Stock Titan
Omada Health, Inc.: Strategic Growth and Market Penetration Drive Buy Rating - TipRanks
Finanzdaten der Omada Health Inc-Aktie (OMDA)
Es liegen keine Finanzdaten für Omada Health Inc (OMDA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
5.18%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):